- All sections
- C - Chemistry; metallurgy
- C12N - Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media
- C12N 5/12 - Fused cells, e.g. hybridomas
Patent holdings for IPC class C12N 5/12
Total number of patents in this class: 421
10-year publication summary
12
|
24
|
28
|
28
|
40
|
20
|
16
|
19
|
3
|
6
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Regeneron Pharmaceuticals, Inc. | 3650 |
11 |
Beth Israel Deaconess Medical Center, Inc. | 844 |
8 |
Dana-Farber Cancer Institute, Inc. | 2455 |
8 |
AVEO Pharmaceuticals, Inc. | 86 |
6 |
Genentech, Inc. | 3742 |
5 |
Amgen Fremont Inc. | 44 |
5 |
Kyoto University | 2732 |
5 |
Amgen Inc. | 3779 |
4 |
ABS Global, Inc. | 126 |
4 |
Arius Research Inc. | 25 |
4 |
Daiichi Sankyo Company, Limited | 1829 |
4 |
Kagoshima University | 284 |
4 |
NB Health Laboratory Co., Ltd. | 24 |
4 |
Redcoat Solutions, Inc. | 11 |
4 |
University Health Network | 979 |
4 |
Xiamen University | 488 |
4 |
Kyowa Kirin Co., Ltd. | 322 |
4 |
The Regents of the University of California | 18943 |
3 |
Pfizer Inc. | 3322 |
3 |
Board of Regents, The University of Texas System | 5370 |
3 |
Other owners | 324 |